The Globe and Mail reports in its Saturday, Jan. 4, edition that DRI Healthcare Trust was a top pick for CIBC Asset Management manager Craig Jerusalim last year. The Globe's Darcy Keith writes that DRI remains a top pick for 2025. Mr. Jerusalim says in a note: "DRI, which we believe will continue to compound double digits for the foreseeable future, given the tremendous mismatch between its current price and our expected book value. DRI is a diversified health care investor seeking to monetize pharmaceutical royalties of innovative drugs and therapeutics. We consider the company to be lower risk given its highly predictable cash flows from patented pharmaceutical royalty streams. Its niche offering is in high demand, driven by growth in R&D and the significant need for external capital. Resilience of pharmaceutical sales during economic downturns should provide downside protection and relative outperformance throughout the economic cycle." The Globe reported on Aug. 8 that Mr. Jerusalim had recommended buying DRI when it was trading at $12.87. The Globe reported on Nov. 6 that RBC Capital analyst Douglas Miehm had reaffirmed his "outperform" recommendation for DRI. The units could then be had for $13.85.